- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Medicenna Therapeutics Corp: Medicenna sets out plans, milestones for 2026 | 1 | Stockwatch | ||
| Do | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook | 821 | GlobeNewswire (Europe) | Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential... ► Artikel lesen | |
| 10.12.25 | Medicenna Therapeutics Corp.: Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors | 122 | GlobeNewswire (Europe) | MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case... ► Artikel lesen | |
| 13.11.25 | Medicenna Therapeutics GAAP EPS of -C$0.06 | 1 | Seeking Alpha | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | Medicenna Therapeutics Corp: Medicenna joins Fondazione Melanoma for MDNA11 trial | 1 | Stockwatch | ||
| 06.11.25 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 23.10.25 | Medicenna Therapeutics Corp.: Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 | 227 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 01.10.25 | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 26.09.25 | Medicenna Therapeutics Corp: Medicenna shareholders approve AGM resolutions | 1 | Stockwatch | ||
| 25.09.25 | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of Shareholders | 85 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 05.09.25 | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 04.08.25 | H.C. Wainwright bestätigt Kaufempfehlung für Medicenna mit Kursziel von 2,50 $ | 2 | Investing.com Deutsch | ||
| 04.08.25 | H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target | 1 | Investing.com | ||
| 04.08.25 | H.C. Wainwright reiterates Buy rating on Medicenna stock with $2.50 target | 1 | Investing.com | ||
| 01.08.25 | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
| 01.08.25 | Medicenna Therapeutics Corp. Q1 Loss Rises | 1 | RTTNews | ||
| 01.08.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 165 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
| 31.07.25 | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
| 26.06.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 358 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen | |
| 13.02.25 | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 234 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 324,08 | 0,00 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| QIAGEN | 45,365 | -5,49 % | Märkte am Morgen: Qiagen, Klöckner & Co., Netflix, 3M, Johnson & Johnson | Die Zollankündigungen von Donald Trump haben den deutschen Aktienmarkt weiter im Griff. Nach den Verlusten vom Montag gab der DAX auch gestern deutlich ab. Am Ende lag er 1,03 Prozent tiefer bei 24.703... ► Artikel lesen | |
| ARCELLX | 72,17 | 0,00 % | Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials | ||
| APOGEE THERAPEUTICS | 82,04 | 0,00 % | Apogee Therapeutics auf Rekordhoch: Aktie erreicht 81,0 USD | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 70,93 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements |
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 90,85 | 0,00 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| NURIX THERAPEUTICS | 18,240 | 0,00 % | BTIG reiterates Buy rating on Nurix stock with $30 price target | ||
| BEAM THERAPEUTICS | 30,965 | 0,00 % | Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment | ||
| DAY ONE BIOPHARMACEUTICALS | 12,120 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| NUVALENT | 105,93 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,395 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ALUMIS | 26,050 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| ERASCA | 9,805 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,550 | 0,00 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.